Navigation Links
UofL researcher to develop oral health plan for those with IDD
Date:11/3/2011

People with intellectual and developmental disabilities living in family or group homes are less likely to receive routine dental care than those living in institutions, according to University of Louisville School of Dentistry associate professor Catherine Binkley, D.D.S., Ph.D. These individuals also are more likely than the general population to have poor oral hygiene, increased decay and gum disease, factors that may contribute to respiratory infections -- including pneumonia.

A $308,000 National Institutes of Health grant will allow Binkley and Knowlton Johnson, PhD, senior scientist, Pacific Institute for Research and Evaluation, to conduct a two-year pilot study to pilot an intervention program for caregivers of those with IDD.

"Many social and behavioral barriers contribute to oral health disparities in people with IDD including the resistance of many community dentists to accept Medicaid or patients with special needs, the lack of oral health literacy on the part of caregivers and uncooperative behaviors of persons with IDD when caregivers or dentists attempt to provide care," Binkley said.

The plan involves a case management strategy an approach that has been effective in managing type II diabetes and obesity in adults and type I diabetes and asthma in children. It is designed to give caregivers - parents, guardians and staff members - knowledge and skills in providing or supervising oral hygiene for the IDD participant.

Initially, a dental hygienist assigned to the case manager role will meet with the caregiver and go over the results of the IDD participant's oral exam. They'll develop an oral health plan that includes setting goals to overcome informational, physical and behavioral obstacles to oral health.

Caregivers will participate in educational sessions and learn how to perform proper oral hygiene techniques such as brushing the teeth of a cognitively impaired person. The case manager will help the
'/>"/>

Contact: Julie Heflin
julie.heflin@louisville.edu
502-852-7987
University of Louisville
Source:Eurekalert

Page: 1 2

Related biology news :

1. Wistar Institute researcher receives New Innovator award from NIH
2. NC State researchers get to root of parasite genome
3. Researchers find animal with ability to survive climate change
4. Researchers find an essential gene for forming ears of corn
5. Researchers note differences between people and animals on calorie restriction
6. Researcher working on destruction of chemical weapons
7. Researchers study acoustic communication in deep-sea fish
8. Researchers discover that growing up too fast may mean dying young in honey bees
9. Researchers study how pistachios may improve heart health
10. UI researchers find potentially toxic substance present in Chicago air
11. Researchers develop new self-training gene prediction program for fungi
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/8/2015)... , July 8, 2015 Summary ... and the fourth most fatal, with a mortality rate ... poor prognosis of pancreatic cancer patients has highlighted a ... which is not being met by the current market. ... array of products with varying molecule types and mechanisms ...
(Date:7/8/2015)... DIEGO , July 8, 2015  Trovagene, ... cell-free molecular diagnostics, today announced the launch of ... the Company,s Precision Cancer Monitoring℠ (PCM) technology for ... receiving one or a combination of the novel ... Opdivo® (nivolumab), a PD-1 inhibitor. The 50-patient study ...
(Date:7/7/2015)... , June 30, 2015 ... announced the addition of the "Capacitive Fingerprint ... To this date, fingerprint sensing technology ... and fingerprint sensors are well developed. This patent ... technology. The domain of capacitive fingerprint ...
Breaking Biology News(10 mins):Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 2Frontier Pharma: Pancreatic Cancer - Identifying and Commercializing First-in-Class Innovation 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 2Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 3Trovagene Initiates Study to Monitor Response to Immunotherapy in Melanoma Patients Using its Precision Cancer Monitoring Platform 4Worldwide Capacitive Fingerprint Sensors Patent Landscape Market Report 2015-2020 - Main IP Holders include Seiko Epson, AuthenTec, Sony and STMicroelectronics 2
... (NYSE: A) today announced that it has for the ... annotation information for all of its microarrays. The release ... research and cross-platform data comparison. , "Full release of ... for Agilent to take," said Catherine Ball, president of ...
... with huge 10 centimetre-long nails spoke volumes. But now definitive ... sighting of a grizzly bear. The discovery fuels mounting evidence ... of the polar bear -- Nanuk is having to make ... barren ground grizzly bear (Ursus arctos) was discovered on Melville ...
... growth of the earliest cities in northern China starting ... the result of successful rice farming combined with other ... Although we often associate rice with Chinese agriculture, most ... that was the most important food associated with northern ...
Cached Biology News:Agilent Technologies releases probe sequence, annotation information for all its commercial gene expression microarrays 2Grizzlies set to invade high Arctic? 2
(Date:7/30/2015)... Texas (PRWEB) , ... July 30, 2015 , ... The ... and in-depth study on the current state of the global Propanol market with a ... Sinopec, CNPC, BASF, Eastman, Dow, Carboclor, Mitsui Chemicals, Oxea, ISU Chemical, Sanofi, Royal Dutch ...
(Date:7/30/2015)... , CA (PRWEB) , ... July 30, 2015 ... ... the successful completion of a field clinical study of its canine osteoarthritis stem ... together with Aratana Therapeutics (Kansas City, KS) and will be marketed in the ...
(Date:7/30/2015)... SAN DIEGO, July 30, 2015   Senomyx , ... proprietary taste science technologies to discover, develop, and commercialize ... supply industries, today reported financial results for the second ... half of 2015, we remain on track to achieve ... and Chief Executive Officer of the Company. "Since our ...
(Date:7/30/2015)... 30, 2015 Ascendis Pharma A/S (Nasdaq: ... its innovative TransCon technology to address significant unmet ... a six-month Phase 2 study to evaluate the ... in 53 treatment-naïve, pre-pubertal children with growth hormone ... pleased with the top-line results from our Phase ...
Breaking Biology Technology:Global Propanol Market Technical Data and Manufacturing Analysis 2020 2Global Propanol Market Technical Data and Manufacturing Analysis 2020 3VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 2SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 3SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 4SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 5SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 6SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 7SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 8SENOMYX ANNOUNCES SECOND QUARTER 2015 FINANCIAL RESULTS 9Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 2Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 3Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 4Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 5Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 6Ascendis Pharma A/S Announces Positive Top-line Results from a Phase 2 Pediatric Study of Once-Weekly TransCon Growth Hormone for the Treatment of Growth Hormone Deficiency 7
... July 30 Varian, Inc.,(NasdaqGS: VARI) announced today ... The TPS-compact provides plug-and-play, hydrocarbon free,ultra-high vacuum pumping ... a,light (max weight 19.1kg/42.1lbs.) scroll pump., The ... by,either the Turbo-V 81 MacroTorr(TM) or Turbo-V 301 ...
... July 30 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX:,MS), a ... today,announced that Mr. Kevin Giese, President and CEO, will ... in New York., WHEN: Wednesday August ... Broadway Hotel, New York About BioMS Medical Corp., ...
... , - Shares Acquired From Biggar Limited, ... company,focused on eye disease, vascular disease and cancer, ... in Belgium have together acquired an 8%,stake in ... Limited, a,charitable foundation that is ThromboGenics largest shareholder. ...
Cached Biology Technology:New Turbomolecular Pumping System From Varian, Inc. Delivers Portable, Dry, Ultra-high Vacuum. 2BioMS Medical to present at BMO Healthcare Conference 2ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 2ThromboGenics Announces Private Investors Acquire 8% Stake in the Company 3
C/EBPalpha Antibody Shipping Temperature: Cold Storage Temperature: -20C...
Rabbit polyclonal to VEZT ( Abpromise for all tested applications). Antigen: Full length human VEZT conjugated to GST Entrez Gene ID: 55591 Swiss Protein ID: Q9HBM0...
Mouse monoclonal [CIa] to Ia Antigen (Biotin) ( Abpromise for all tested applications)....
Phospho-TAK1 (Thr184/187) (90C7) Rabbit mAb Shipping Temperature: Cold Storage Temperature: -20C...
Biology Products: